This trial is designed to assess the tolerability, safety, pharmacokinetic profile, and preliminary efficacy of the combination of ZGGS18 and ZG005 in patients with advanced solid tumors, including advanced cervical cancer, hepatocellular carcinoma, neuroendocrine cancer, and lung cancer.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Intravenous infusion
Intravenous infusion
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
RECRUITINGDose limited toxicity(DLT)
Incidence and severity of DLT events
Time frame: up to 21 days
Adverse Event (AE)
Abnormal changes in clinical symptoms, vital signs, physical examination, laboratory tests, electrocardiograph and other examinations.
Time frame: Up to 2 years
Maximum tolerated dose(MTD)
Time frame: Up to 1 years
Recommended phase II dose(RP2D)
Time frame: Up to 1 years
Objective response rate (ORR)
Objective Response Rate as Assessed by Investigator according to RECIST v1.1
Time frame: Up to 2 years
Immunogenicity
Incidence of antidrug antibodies (ADA)
Time frame: Up to 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.